Curative Health Services Secures $10 Million Term Loan; Curative's Credit Facilities Now Total $35 Million.

Business Editors

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--May 20, 2002

Curative Health Services, Inc. (NASDAQ: CURE) announced today that it has secured a 4 year, $10 million term loan facility with Healthcare Business Credit Corporation ("HBCC").

This loan facility is in addition to the $25 million line of credit which was established with HBCC in January 2002, giving Curative an aggregate $35 million in unused credit facilities to fund its acquisition strategy and for general operating purposes.

"Securing this term facility provides us with additional flexibility in funding our plan to aggressively grow our Specialty Pharmacy Services (SPS) business through acquisition." said Curative's Chairman, Joseph Feshbach. "Moreover, we are very pleased with the confidence expressed by HBCC in the Curative strategy as evidenced by this commitment."

About Curative Health Services

Curative Health Services (CURE) delivers superior clinical outcomes and high patient satisfaction for patients experiencing serious medical conditions through two unique business units.

Curative's Specialty Pharmacy Services business unit offers pharmacy products to patients for chronic and critical disease states such as Hemophilia and provides services to help such patients manage the health care process.

Curative Health Services' Specialty Healthcare Services (SHS) business unit is an industry leader in chronic wound care management, consistently achieving an outcome success rate of more than 80 percent. SHS provides a broad continuum of services to health care providers through a nationwide network. This national network of more than 100 hospital-based Wound Care Center programs, has offered comprehensive treatment to over 300,000 patients, achieving more than a 95 percent patient satisfaction rate.

For more information, visit www.curative.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such differences include, but are not limited to, the termination or non-renewal of a material number of contracts, an inability to obtain new contracts, changes in the government regulations relating to the Company's Specialty Healthcare Services or Specialty Pharmacy Services business units, changes in the regulations governing third party reimbursements for the Company's services, manufacturing shortages of products sold by Curative's Specialty Pharmacy Services business unit and the other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Readers of this release are referred to the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and Amendment No. 2 to its Form S-3 filed May 13, 2002 for further discussion of these and other factors that could affect future results.